611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

NurseWise 24-Hour Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

NurseWise 24-Hr Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Cancer
Resources
Basic InformationLatest News
Caregivers Have a Worse View of Cancer Patients' Functional StatusShort-Term Risk of Arterial Embolism Up in Cancer PatientsEndometrial Ablation Doesn't Increase Cancer RiskResearchers ID Genes in Mice That Cause Aggressive Brain CancerMultigene Panel Tests Can ID Hereditary Kidney CancerHospital Volume, Quality Impact Survival in Ovarian CancerPatient Profile Impacts QOL With Radiation Tx in Head, Neck CancerAntiperspirant Use Seems Safe During Breast Cancer Treatment: StudyOpioid Prescription Rates Higher in Cancer SurvivorsCancer Takes Financial Toll, Even With InsuranceFor Cancer Patients in the ER, Delirium Linked to Poor OutcomesBlood Test Can Screen for Rare Sinus Cancer, Study FindsColorectal Cancer Mortality Rates Down in Blacks, Up in WhitesDeaths From Colon Cancer Up Among Younger White AmericansOsteoporosis Meds Up BMD in Nonmetastatic Prostate CancerIntervention May Cut Muscle Loss From RT for Head & Neck CancerNot All 80-, 90-Year-Olds With Rectal Cancer Are TreatedChildhood Cancer Radiation May Cause Unwanted Gene Mutation in SomeNew Treatment Approved for Acute Myeloid LeukemiaYoung Cancer Survivors Struggle to Resume Social ActivitiesIdhifa Approved for Some With Acute Myeloid LeukemiaBreast-Feeding Lowers Mom's Breast Cancer Risk: StudyReview: Positive Link for Alcohol, Nonmelanoma Skin CancerChemo Plus Hyperthermia Active in Advanced Pancreatic CancerThyroid Cancer Tied to Regular Thyroxine Use in HypothyroidismInterval Training Cuts CVD Risk in Testicular Cancer SurvivorsTotal, Saturated Fat Linked to Increased Risk of Lung CancerTreatment Costs Can Be Another Blow to Cancer PatientsLack of Training Linked to Cancer Patient Caregiver BurdenMelanoma Isn't the Only Serious Skin CancerMany With Cancer Hospitalized, Undergo Imaging at End of Life$100 Sweetens the Pot for a ColonoscopyVascular Targeted Photodynamic Tx Aids Low-Risk Prostate CancerObesity in Teen Years Tied to Colon Cancer Risk in AdulthoodASCO Addresses Cancer Drug PricingSenator McCain Faces a Tough Cancer FoeMore Patients OK'd for Cancer Trials Under Obamacare: StudyInsured, But Still Barred From Top-Tier Cancer CentersMany Terminal Cancer Patients Remain in DenialSingle-Dose PCV13 Immunogenic, Safe in Pediatric OncologyDoctors' Group Offers Ideas for Easing Cancer Costs'Nipple-Sparing' Mastectomies Don't Raise Odds of Cancer's Return: StudyNerlynx Approved to Help Prevent Breast Cancer's ReturnLittle Evidence That Vasectomy Raises Prostate Cancer RiskWait-and-Scan Strategy Feasible for Head, Neck ParagangliomaHigher Nodal Yield Tied to Lower Mortality in Oral Cavity CancerChange to Cervical Screening Guidelines Impacted ChlamydiaBlood Test for Early Detection of Pancreatic Cancer Feasible'Observation' Best Option for Most Low-Risk Prostate CancerAre Big Men More Prone to Aggressive Prostate Cancer?
LinksBook ReviewsSelf-Help Groups
Related Topics

Medical Disorders
Pain Management

Multigene Panel Tests Can ID Hereditary Kidney Cancer


HealthDay News
Updated: Aug 11th 2017

new article illustration

FRIDAY, Aug. 11, 2017 (HealthDay News) -- For patients who lack distinguishing clinical characteristics of known hereditary kidney cancer syndromes, panel testing may be useful for identifying hereditary cancer, according to a study published online Aug. 8 in Cancer.

Kevin A. Nguyen, from the Yale School of Medicine in New Haven, Conn., and colleagues retrospectively reviewed test results and clinical data from 1,235 patients who underwent targeted multigene panel testing of up to 19 genes associated with hereditary kidney cancer. The authors assessed the frequency of positive, inconclusive, and negative results.

The median age at diagnosis was 46 years, which was significantly younger than that of the U.S. population of individuals with kidney cancer. The researchers found that 6.1, 75.5, and 18.4 percent of participants had positive, negative, and inconclusive results, respectively. Folliculin and fumarate hydratase were the most commonly altered genes (altered in 1.8 and 1.3 percent of patients, respectively). The highest rates of variants of unknown significance were in Tuberous Sclerosis Complex 2, mesenchymal epithelial transition factor proto-oncogene, and PMS1 homolog 2, seen in 2.7, 2.2, and 1.7 percent of patients, respectively. The only factor that was identified as predictive of a positive test on multivariate logistic regression was early age of onset (odds ratio, 0.975), which may be an identifying characteristic of low-penetrant syndromes.

"Panel tests may be particularly useful for patients who lack distinguishing clinical characteristics of known hereditary kidney cancer syndromes," the authors write. "The current results support the use of early age of onset for genetic counseling and/or testing."

Two authors are employees of Ambry Genetics, which provided the authors with the dataset for the study.

Abstract
Full Text (subscription or payment may be required)